Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR

Leukemia

Volumn 13, Issue 11, 1999, Pages 1825-1832

  Emig, M ^a   Saussele S ^a   Wittor, H ^b   Weisser A ^a   Reiter, A ^a   Willer, A ^a   Berger, U ^a   Hehlmann, R ^a   Cross, N C P ^c   Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Chronic myelogenous leukemia; Minimal residual disease; Quantitative PCR; Real time PCR

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; FLUORESCENT DYE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA PROBE; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METAPHASE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0344614012     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401566     Document Type: Article

References (43)

1. Sawyers CL. Chronic myeloid leukemia. New Engl J Med 1999; 340: 1330-1340.
2. Cross NCP. Assessing residual leukaemia. Baillières Clin Haematol 1997; 10: 389-403.
3. Lion T. Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clincal aspects. Leukemia 1996; 10: 896-906.
4. Morley A. Quantifying leukemia. New Engl J Med 1998; 339: 627-629.
5. Mensink E, van de Locht A, Schattenberg A, Linders E, Schaap N, Guerts van Kessel A, de Witte T. Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR. Bc J Haematol 1998; 102: 768-774.
6. Preudhomme C, Révillion F, Merlat A, Hornez L, Roumier C, Duflos-Grardel N, Jouet JP, Cosson A, Peyrat JP, Fenaux P. Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay. Leukemia 1999; 13: 957-964.
7. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997; 22: 130-138.
8. Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, Balis UJ. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997; 22: 176-181.
9. ISCN. An International System tor Human Cytogenetic Nomenclature. In: Harnden DG, Klinger HP (eds). Karger: Basel, 1985.
10. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Intern Med 1995; 122: 254-261.
11. Grossman A, Silver RT, Szatrowski TP, Gutfriend A, Verma RS, Benn PA. Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia 1991; 5: 540-547.
12. Reiter A, Skladny H, Hochhaus A, Seifarth W, Heimpel H, Bartram CR, Cross NCP, Hehlmann R. Molecular response of CML patients treated with interferon-α monitored by quantitative Southern blot analysis. Br J Haematol 1997; 97: 86-93.
13. Cross NCP, Feng L, Bungey J, Goldman JM. Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction. Leuk Lymphoma 1993; 11 (Suppl. 1): 39-43.
14. Cross NCP, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia 1994; 8: 186-189.
15. van Rhee F, Marks DI, Lin F, Szydlo RM, Hochhaus A, Treleaven J, Delord C, Cross NCP, Goldman JM. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
16. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
17. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-α therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549-1555.
18. Chissoe SL, Bodenteich A, Wang YF, Wang YP, Burian D, Clifton SW, Crabtree J, Freeman A, Iyer K, Jian L, Ma Y, McLaury HJ, Pan HQ, Sarhan OH, Toth S, Wang Z, Zhang G, Heisterkamp N, Grotfen J. Roe BA. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. Genomics 1995; 27: 67-82.
19. Chen EY, Cheng A, Lee A, Kuang WJ, Hillier L, Green P, Schlessinger D, Ciccodicola A, D'Urso M. Sequence of human glucose-6-phosphate dehydrogenase cloned in plasmids and a yeast artificial chromosome. Genomics 1991; 10: 792-800.
20. Hochhaus A, Lin F, Reiter A, Skladny H, van Rhee F, Shepherd PCA, Allan NC, Hehlmann R, Goldman JM, Cross NCP. Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-a. Br J Haematol 1995; 91: 126-131.
21. Lin F, Kirkland MA, van Rhee F, Chase A, Coulthard S, Bungey J, Goldman JM, Cross NCP. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 1996; 18: 1147-1152.
22. Lin F, van Rhee F, Goldman JM, Cross NCP. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 1996; 87: 4473-4478.
23. Gaiger A, Lion T, Kalhs P, Mitterbauer G, Henn T, Haas O, Fodinger M, Kier P, Forstinger C, Quehenberger P, Hinterberger W, Jäger U, Linkesch W, Mannhalter C, Lechner K. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 1993; 7: 1766-1772.
24. Lion T, Henn T, Gaiger A, Kalhs P, Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993; 341: 275-276.
25. van Rhee F, Lin F, Cullis JO, Spencer A, Cross NCP, Chase A, Garicochea B, Bungey J, Barren J, Goldman JM. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 1994; 83: 3377-3383.
26. Raanani P, Dazzi F, Sohal J, Szydlo R, van Rhee F, Reiter A, Lin F, Goldman JM, Cross NCP. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997; 99: 945-950.
27. Bohling SD, King TC, Wittwer CT, Elenitoba-Johnson KSJ. Rapid simultaneous amplification and detection of the MBR/JH chromosomal translocation by fluorescence melting curve analysis. Am J Pathol 1999; 154: 97-103.
28. Gibson UEM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
29. Heid CA, Stevens I, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res 1996; 6: 986-994.
30. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology 1992; 10: 413-417.
31. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
32. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NCP. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome negative chronic myelogenous leukemia. Blood 1996; 88: 2236-2240.
33. BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 1994; 8: 208-211.
34. Pane F, Frigeri F, Sindona M, Luciano L, Ferrara F, Cimino R, Meloni G, Saglio G, Salvatore F, Rotoli B. Neutrophilic-chronic myelogenous leukemia (CML-N): a distinct disease with a specific marker (BCR-ABL with c3a2 junction). Blood 1996; 88: 2410-2414.
35. van der Plas DC, Soekarman D, van Gent AM, Grosveld G, Hagemeijer A. bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient. Leukemia 1991; 5: 457-461.
36. Paldi Haris P, Barta A, Lengyel L, Batai A, Masszi T, Remenyi P, Denes R, Paloczi K, Kelemen E, Foldi J. Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon (letter). Leukemia 1994; 8: 1791.
37. Iwata S, Mizutani S, Nakazawa S, Yata J. Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2. Leukemia 1994; 8: 1696-1702.
38. Lion T. Control genes in reverse transcriptase-polymerase chain reaction assays. Leukemia 1996; 10: 1527-1528.
39. Soutar RL, Dillon J, Ralston SH. Control genes for reverse-transcription polymerase chain reaction: a comparison of beta actin and glyceraldehyde phosphate dehydrogenase. Br J Haematol 1997; 97: 247-248.
40. Cross NCP, Lin F, Goldman JM. Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR). Br J Haematol 1994; 87: 218.
41. Taylor JJ, Haesman PA. Control genes for reverse transcriptase/polymerase chain reaction (RT-PCR). Br J Haematol 1994; 86: 444-447.
42. Hook EB. Exclusion of chromosomal mosaicism: tables of 90%, 95%, and 99% confidence limits and comments on use. Am J Hum Genet 1977; 29: 94-97.
43. Lin F, Goldman JM, Cross NCP. A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol 1994; 86: 683-685.